KDM6A controls immunogenicity in MM

The current lack of mechanistic understanding in KS is a limitation that plagues the rational combination of antitumor and the discovery of KSHV, there is no single patient-derived cell line to test the effect of immune modulatory agents on the virus or the cancer. If there was one, how well would a cell line replicate the cytokine cross talk within the tumor environment? The field is on thin ice, trying to link patient responses to established theories about inflammation. We have more before, but without a molecularly defined basis for decision-making, how far can biomarker correlations alone inform clinical practice? "KS is not one disease, but many" will be a curse and an opportunity for the next 40 years of KS research.